GOBLET is a multi-arm Phase 1/2 trial in advanced/metastatic GI tumors led by AIO, testing pelareorep in combination with atezolizumab and various chemotherapies, with a strong focus on biomarkers and objective response rates.

The GOBLET design includes five treatment groups across GI indications and prioritizes objective response rate and safety as primary endpoints, supported by multiple biomarker and efficacy sub-analyses.

AWARE-1 is a window-of-opportunity study in early-stage breast cancer evaluating pelareorep with and without checkpoint blockade, and assessing CelTIL and biomarker endpoints.

Pelareorep is positioned to improve responses in pancreatic, colorectal, breast, and other GI cancers, with FDA Fast Track designation for colorectal and pancreatic cancer.

Oncolytics is pursuing registrational programs in GI cancers and aims to leverage pelareorep to boost immunotherapy activity, especially in RAS-driven cancers.

The company plans ongoing and future registrational efforts in GI cancers and to validate biomarkers, including a 14-protein signature, to guide therapy and trial design.

In first-line metastatic pancreatic ductal adenocarcinoma treated with pelareorep plus atezolizumab and chemotherapy (GOBLET cohort 1), an objective response rate of 62% was observed, exceeding historical chemo-alone responses.

The press release includes forward-looking statements and risk factors, and directs readers to follow updates and the company website for more information.

Two abstracts were accepted for presentation at AACR 2026, highlighting pelareorep as an immune-priming backbone across tumor types, including RAS-driven cancers.

Further AACR 2026 abstracts discuss GOBLET cohort 1 in metastatic pancreatic ductal adenocarcinoma and AWARE-1 in breast cancer, with translational data on pelareorep’s immune-priming role.

The AACR presentations include translational and mechanistic data on pelareorep across multiple tumor types, emphasizing its potential to enhance immunotherapy activity.

Pelareorep stimulates RAS-specific T-cell clones in GI cancers, suggesting activity against RAS-mutated tumors and potential synergy with immunotherapies in RAS-driven cancers.